Skip to content

US · LONA · BIOTECHNOLOGY

LeonaBio, Inc. (LONA) intrinsic value and stock valuation

$2.05as of 2026-11-21 · Mkt cap 30.29M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

LeonaBio, Inc. DCF and intrinsic value

InvestorsCraft values LONA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LONA’s statements →

LeonaBio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Bothell, WA 98011 leonabio.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-105.61M
20182025
Free cash flow
-$-45.73M
20182025
Total equity
$27.8M-36.7% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-102.27M-$-100.9M-$-125.47M-$-104.02M-$-64.02M
Net income-$-105.61M-$-96.94M-$-117.67M-$-95.64M-$-54.85M
EPSd-$-24.68M-$-25.18M-$-30.97M-$-25.37M-$-14.86M
Operating cash flow-$-45.73M-$-97.17M-$-100.75M-$-72.47M-$-43.1M
Capital expenditure$0.00-$-30K-$-300K-$-1.14M-$-1.57M
Free cash flow-$-45.73M-$-97.2M-$-101.06M-$-73.61M-$-44.67M
Total assets$92.2M$58.8M$160.3M$258.2M$332M
Total debt$800K$1.22M$1.58M$1.91M$1.92M
Net debt-$-68.47M-$-47.22M-$-89M-$-94.06M-$-108.62M
Total equity$27.8M$44.8M$130.2M$235.1M$321.1M
Cash and short-term investments$88.3M$51.3M$147.4M$200.3M$253.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$68.1M$0.00$0.00$0.00$480K
Gross profit-$-68.09M$0.00$0.00$0.00-$-480K
Research and development expenses$17.5M$70.7M$93.8M$61.5M$42.8M
Selling, general and administrative expenses$16.7M$26.1M$33.3M$32.6M$21.2M
Other expenses$0.00$4.13M-$-1.63M$10M-$-480K
Operating expenses$34.2M$100.9M$125.5M$104M$63.5M
Cost and expenses$102.3M$100.9M$125.5M$104M$64M
Interest income$0.00$3.96M$7.64M$3.22M$340K
Interest expense$0.00$0.00$0.00$24.3M$0.00
Depreciation and amortization$970K$970K$970K$840K$480K
Ebitda-$-33.21M-$-95.81M-$-125.97M-$-88.01M-$-54.37M
Operating income-$-102.27M-$-100.9M-$-125.47M-$-104.02M-$-64.02M
Total other income/expenses, net-$-3.34M$3.96M$7.79M$8.38M$9.17M
Income before tax-$-105.61M-$-96.94M-$-117.67M-$-95.64M-$-54.85M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-105.61M-$-96.94M-$-117.67M-$-95.64M-$-54.85M
Weighted average shares outstanding$4.28M$3.85M$3.8M$3.77M$3.69M
Weighted average diluted shares outstanding$4.28M$3.85M$3.8M$3.77M$3.69M
Balance sheet
20252024202320222021
Cash and short-term investments$88.3M$51.3M$147.4M$200.3M$253.8M
Net receivables$0.00$0.00$1.63M$1.23M$2.34M
Inventory$0.00$0.00$0.00-$-1.23M$0.00
Total current assets$89.5M$54.8M$154.7M$207.5M$260.8M
Property, plant and equipment, net$2.01M$3.25M$4.44M$5.32M$5.22M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$630K$630K$44.8M$65.9M
Total non-current assets$2.69M$3.94M$5.52M$50.6M$71.2M
Total assets$92.2M$58.8M$160.3M$258.2M$332M
Accounts payable$4.59M$320K$130K$2.5M$570K
Short-term debt$470K$410K$370K$330K$290K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$47.5M$13.1M$28.8M$21.4M$9.29M
Long-term debt$340K$800K$1.22M$1.58M$1.63M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$16.9M$800K$1.22M$1.58M$1.63M
Capital lease obligations$470K$1.22M$1.58M$1.91M$1.92M
Total liabilities$64.4M$13.9M$30.1M$23M$10.9M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-511.75M-$-406.15M-$-309.21M-$-191.53M-$-95.89M
Accumulated other comprehensive income (loss)-$0.00$0.00-$-350K-$-1.96M-$-390K
Total equity$27.8M$44.8M$130.2M$235.1M$321.1M
Total investments$19.1M$3.47M$57.5M$149.2M$209.2M
Total debt$800K$1.22M$1.58M$1.91M$1.92M
Net debt-$-68.47M-$-47.22M-$-89M-$-94.06M-$-108.62M
Cash flow statement
20252024202320222021
Net income-$-105.61M-$-96.94M-$-117.67M-$-95.64M-$-54.85M
Depreciation and amortization$970K$460K$970K$1.05M$480K
Stock-based compensation$6.1M$11.1M$10.6M$10.6M$4.62M
Change in working capital-$-19.38M-$-11.98M$6.53M$11.9M$6M
Accounts receivable$0.00$1.63M-$-400K$1.11M-$-1.04M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-21.34M-$-5.75M$7.37M$2.1M$5.15M
Net cash provided by operating activities-$-45.73M-$-97.17M-$-100.75M-$-72.47M-$-43.1M
Investments in property, plant and equipment$0.00-$-30K-$-300K-$-1.14M-$-1.57M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-15.89M$54.8M$95.1M$57.7M-$-4.08M
Common stock issued$0.00$190K$490K$650K$96.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$82.5M$190K$490K$650K$97.1M
Net change in cash$20.8M-$-42.15M-$-5.17M-$-14.57M$49.9M
Cash at end of period$69.9M$49.1M$91.2M$96M$110.5M
Operating cash flow-$-45.73M-$-97.17M-$-100.75M-$-72.47M-$-43.1M
Capital expenditure$0.00-$-30K-$-300K-$-1.14M-$-1.57M
Free cash flow-$-45.73M-$-97.2M-$-101.06M-$-73.61M-$-44.67M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About LeonaBio, Inc.

        LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.

        CEO
        Mark J. Litton
        Employees
        19
        Beta
        2.02

        Explore

        Frequently asked questions

        What is the intrinsic value of LeonaBio, Inc. (LONA)?

        InvestorsCraft does not currently publish an intrinsic value for LONA. How the IC value is calculated.

        Is LONA undervalued?

        InvestorsCraft does not publish an undervaluation signal for LONA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.